10-KPeriod: FY1998

ELI LILLY & Co Annual Report, Year Ended Dec 31, 1998

Filed March 26, 1999For Securities:LLY

Summary

Eli Lilly and Company's 1998 10-K filing, filed on March 26, 1999, reflects a company operating within the dynamic pharmaceutical industry. While specific financial performance details are not directly extractable from the provided directory listing, the filing would typically detail the company's financial condition, results of operations, and cash flows for the fiscal year ended December 30, 1998. Investors would look for information on revenue growth drivers, product pipelines, research and development investments, and any significant legal or regulatory matters that could impact future performance. Given the era, key products and therapeutic areas likely played a crucial role in the company's performance. Investors would be interested in the company's competitive positioning, its strategies for market expansion, and its ability to bring new, innovative treatments to market. The filing would also address risk factors, management discussion and analysis (MD&A), and details about the company's business segments, providing a comprehensive overview of its operational landscape.

Key Highlights

  • 1The 10-K filing covers the fiscal year ending December 30, 1998.
  • 2The filing was submitted on March 25, 1999, by Eli Lilly & Company (LLY).
  • 3The document is a standard Annual Report (10-K) as per SEC regulations.
  • 4The filing is part of the EDGAR database, accessible through the SEC.
  • 5The provided content is a directory listing of the filing's components, not the full report content.
  • 6Key financial and operational details are expected to be within the actual filed documents (e.g., .txt, .htm files) not fully presented here.
  • 7Investors would typically analyze the full report for financial performance, product pipeline, R&D, and risk factors.

Frequently Asked Questions

The provided directory listing does not contain specific financial figures for Eli Lilly's 1998 performance. A full review of the 10-K filing, particularly the financial statements and Management's Discussion and Analysis sections, would be required to ascertain revenue, profitability, and other key financial metrics for the year ended December 30, 1998.

Information regarding Eli Lilly's specific products and therapeutic areas driving performance in 1998 is not detailed in the provided directory listing. The full 10-K report would typically outline the company's product portfolio, sales contributions by segment, and its focus areas for research and development.

The directory listing does not provide details on the risks faced by Eli Lilly in 1998. The 'Risk Factors' section within the actual 10-K filing would comprehensively address potential challenges such as regulatory hurdles, patent expirations, competitive pressures, and litigation.

The complete 10-K filing, identified by accession number 0000950131-99-001772, can be accessed through the SEC's EDGAR database. Investors can search for company filings on the SEC's website or through financial data providers.